|
1
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Tepper J, Krasna MJ, Niedzwiecki D, Hollis
D, Reed CE, Goldberg R, Kiel K, Willett C, Sugarbaker D and Mayer
R: Phase III trial of trimodality therapy with cisplatin,
fluorouracil, radiotherapy, and surgery compared with surgery alone
for esophageal cancer: CALGB 9781. J Clin Oncol. 26:1086–1092.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Nishino M, Ramaiya NH, Hatabu H and Hodi
FS: Monitoring immune-checkpoint blockade: Response evaluation and
biomarker development. Nat Rev Clin Oncol. 14:655–688. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sharpe AH and Freeman GJ: The B7-CD28
superfamily. Nat Rev Immunol. 2:116–126. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Francisco LM, Sage PT and Sharpe AH: The
PD-1 pathway in tolerance and autoimmunity. Immunol Rev.
236:219–242. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ceeraz S, Nowak EC and Noelle RJ: B7
family checkpoint regulators in immune regulation and disease.
Trends Immunol. 34:556–563. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Jesinghaus M, Steiger K, Slotta-Huspenina
J, Drecoll E, Pfarr N, Meyer P, Konukiewitz B, Bettstetter M,
Wieczorek K, Ott K, et al: Increased intraepithelial CD3+
T-lymphocytes and high PD-L1 expression on tumor cells are
associated with a favorable prognosis in esophageal squamous cell
carcinoma and allow prognostic immunogenic subgrouping. Oncotarget.
8:46756–46768. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Jiang Y, Lo AWI, Wong A, Chen W, Wang Y,
Lin L and Xu J: Prognostic significance of tumor-infiltrating
immune cells and PD-L1 expression in esophageal squamous cell
carcinoma. Oncotarget. 8:30175–30189. 2017.PubMed/NCBI
|
|
10
|
Zhang W, Pang Q, Zhang X, Yan C, Wang Q,
Yang J, Yu S, Liu X, Pan Y, Yuan Z, et al: Programmed death-ligand
1 is prognostic factor in esophageal squamous cell carcinoma and is
associated with epidermal growth factor receptor. Cancer Sci.
108:590–597. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yamashita K, Watanabe M, Mine S, Fukudome
I, Okamura A, Yuda M, Hayami M and Imamura Y: The impact of the
Charlson comorbidity index on the prognosis of esophageal cancer
patients who underwent esophagectomy with curative intent. Surg
Today. 48:632–639. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Edge SB and Compton CC: The American Joint
Committee on Cancer: The 7th edition of the AJCC cancer staging
manual and the future of TNM. Ann Surg Oncol. 17:1471–1474. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chen LJ, Sun J, Wu HY, Zhou SM, Tan Y, Tan
M, Shan BE, Lu BF and Zhang XG: B7-H4 expression associates with
cancer progression and predicts patient's survival in human
esophageal squamous cell carcinoma. Cancer Immunol Immunother.
60:1047–1055. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Camp RL, Dolled-Filhart M and Rimm DL:
X-tile: A new bio-informatics tool for biomarker assessment and
outcome-based cut-point optimization. Clin Cancer Res.
10:7252–7259. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wakita A, Motoyama S, Nanjo H, Sato Y,
Yoshino K, Sasaki T, Kawakita Y, Liu J, Imai K, Saito H and
Minamiya Y: PD-L1 expression is a prognostic factor in patients
with thoracic esophageal cancer treated without adjuvant
chemotherapy. Anticancer Res. 37:1433–1441. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chen K, Cheng G, Zhang F, Zhang N, Li D,
Jin J, Wu J, Ying L, Mao W and Su D: Prognostic significance of
programmed death-1 and programmed death-ligand 1 expression in
patients with esophageal squamous cell carcinoma. Oncotarget.
7:30772–30780. 2016.PubMed/NCBI
|
|
17
|
Loos M, Langer R, Schuster T, Gertler R,
Walch A, Rauser S, Friess H and Feith M: Clinical significance of
the costimulatory molecule B7-H1 in Barrett carcinoma. Ann Thorac
Surg. 91:1025–1031. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chen L, Deng H, Lu M, Xu B, Wang Q, Jiang
J and Wu C: B7-H1 expression associates with tumor invasion and
predicts patient's survival in human esophageal cancer. Int J Clin
Exp Pathol. 7:6015–6023. 2014.PubMed/NCBI
|
|
19
|
Chen MF, Chen PT, Chen WC, Lu MS, Lin PY
and Lee KD: The role of PD-L1 in the radiation response and
prognosis for esophageal squamous cell carcinoma related to IL-6
and T-cell immunosuppression. Oncotarget. 7:7913–7924.
2016.PubMed/NCBI
|
|
20
|
Huang B, Chen L, Bao C, Sun C, Li J, Wang
L and Zhang X: The expression status and prognostic significance of
programmed cell death 1 ligand 1 in gastrointestinal tract cancer:
A systematic review and meta-analysis. Onco Targets Ther.
8:2617–2625. 2015.PubMed/NCBI
|
|
21
|
Wu P, Wu D, Li L, Chai Y and Huang J:
PD-L1 and survival in solid tumors: A meta-analysis. PLoS One.
10:e01314032015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Pyo JS, Kang G and Kim JY: Prognostic role
of PD-L1 in malignant solid tumors: A meta-analysis. Int J Biol
Markers. 32:e68–e74. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang X, Teng F, Kong L and Yu J: PD-L1
expression in human cancers and its association with clinical
outcomes. Onco Targets Ther. 9:5023–5039. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Tanaka K, Miyata H, Sugimura K, Kanemura
T, Hamada-Uematsu M, Mizote Y, Yamasaki M, Wada H, Nakajima K,
Takiguchi S, et al: Negative influence of programmed
death-1-ligands on the survival of esophageal cancer patients
treated with chemotherapy. Cancer Sci. 107:726–733. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
National Comprehensive Cancer Network
(NCCN). Clinical Practice Guidelines in Oncology. Esophageal and
Esophagogastric Junction Cancers. Version 2.2017. 2017.
|
|
26
|
Lim SH, Hong M, Ahn S, Choi YL, Kim KM, Oh
D, Ahn YC, Jung SH, Ahn MJ, Park K, et al: Changes in tumour
expression of programmed death-ligand 1 after neoadjuvant
concurrent chemoradiotherapy in patients with squamous oesophageal
cancer. Eur J Cancer. 52:1–9. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Formenti SC and Demaria S: Combining
radiotherapy and cancer immunotherapy: A paradigm shift. J Natl
Cancer Inst. 105:256–265. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Dovedi SJ, Adlard AL, Lipowska-Bhalla G,
McKenna C, Jones S, Cheadle EJ, Stratford IJ, Poon E, Morrow M,
Stewart R, et al: Acquired resistance to fractionated radiotherapy
can be overcome by concurrent PD-L1 blockade. Cancer Res.
74:5458–5468. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kelly RJ, Zaidi AH, Smith MA, Omstead AN,
Kosovec JE, Matsui D, Martin SA, DiCarlo C, Werts ED, Silverman JF,
et al: The dynamic and transient immune microenvironment in locally
advanced esophageal adenocarcinoma post chemoradiation. Ann Surg.
2017.PubMed/NCBI
|
|
30
|
Zeng J, See AP, Phallen J, Jackson CM,
Belcaid Z, Ruzevick J, Durham N, Meyer C, Harris TJ, Albesiano E,
et al: Anti-PD-1 blockade and stereotactic radiation produce
long-term survival in mice with intracranial gliomas. Int J Radiat
Oncol Biol Phys. 86:343–349. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Leng C, Li Y, Qin J, Ma J, Liu X, Cui Y,
Sun H, Wang Z, Hua X, Yu Y, et al: Relationship between expression
of PD-L1 and PD-L2 on esophageal squamous cell carcinoma and the
antitumor effects of CD8+ T cells. Oncol Rep.
35:699–708. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Chen K, Zhu Z, Zhang N, Cheng G, Zhang F,
Jin J, Wu J, Ying L, Mao W and Su D: Tumor-infiltrating CD4+
lymphocytes predict a favorable survival in patients with operable
esophageal squamous cell carcinoma. Med Sci Monit. 23:4619–4632.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhang W, Pang Q, Yan C, Wang Q, Yang J, Yu
S, Liu X, Yuan Z, Wang P and Xiao Z: Induction of PD-L1 expression
by epidermal growth factor receptor-mediated signaling in
esophageal squamous cell carcinoma. Onco Targets Ther. 10:763–771.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Sudo T, Nishida R, Kawahara A, Saisho K,
Mimori K, Yamada A, Mizoguchi A, Kadoya K, Matono S, Mori N, et al:
Clinical impact of tumor-infiltrating lymphocytes in esophageal
squamous cell carcinoma. Ann Surg Oncol. 24:3763–3770. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Li J, Tang Y, Huang L, Yu Q, Hu G, Zou Y
and Yuan X: A high number of stromal tumor-infiltrating lymphocytes
is a favorable independent prognostic factor in M0 (stages I–III)
esophageal squamous cell carcinoma. Dis Esophagus. 30:1–7. 2016.
View Article : Google Scholar
|
|
36
|
Chiu B, Jantuan E, Shen F, Chiu B and
Sergi C: Autophagy-inflammasome interplay in heart failure: A
systematic review on basics, pathways, and therapeutic
perspectives. Ann Clin Lab Sci. 47:243–252. 2017.PubMed/NCBI
|
|
37
|
Apel A, Herr I, Schwarz H, Rodemann HP and
Mayer A: Blocked autophagy sensitizes resistant carcinoma cells to
radiation therapy. Cancer Res. 68:1485–1494. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Chen Y, Song H, Lu Y, Li X, Chen T, Zhang
Y, Xue JX, Liu H, Kan B, Yang G and Fu T: Autophagy inhibition
contributes to radiation sensitization of esophageal squamous
carcinoma cells. Dis Esophagus. 24:437–443. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Clark CA, Gupta HB and Curiel TJ: Tumor
cell-intrinsic CD274/PD-L1: A novel metabolic balancing act with
clinical potential. Autophagy. 13:987–988. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Parsa AT, Waldron JS, Panner A, Crane CA,
Parney IF, Barry JJ, Cachola KE, Murray JC, Tihan T, Jensen MC, et
al: Loss of tumor suppressor PTEN function increases B7-H1
expression and immunoresistance in glioma. Nat Med. 13:84–88. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Dong L, Lv H, Li W, Song Z, Li L, Zhou S,
Qiu L, Qian Z, Liu X, Feng L, et al: Co-expression of PD-L1 and
p-AKT is associated with poor prognosis in diffuse large B-cell
lymphoma via PD-1/PD-L1 axis activating intracellular AKT/mTOR
pathway in tumor cells. Oncotarget. 7:33350–33362. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Afreen S and Dermime S: The
immunoinhibitory B7-H1 molecule as a potential target in cancer:
Killing many birds with one stone. Hematol Oncol Stem Cell Ther.
7:1–17. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Hatogai K, Fujii S, Kojima T, Daiko H,
Nomura S, Doi T, Kitano S, Ohtsu A, Takiguchi Y, Yoshino T and
Ochiai A: Large-scale comprehensive immunohistochemical biomarker
analyses in esophageal squamous cell carcinoma. J Cancer Res Clin
Oncol. 143:2351–2361. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Madore J, Vilain RE, Menzies AM, Kakavand
H, Wilmott JS, Hyman J, Yearley JH, Kefford RF, Thompson JF, Long
GV, et al: PD-L1 expression in melanoma shows marked heterogeneity
within and between patients: Implications for anti-PD-1/PD-L1
clinical trials. Pigment Cell Melanoma Res. 28:245–253. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
McLaughlin J, Han G, Schalper KA,
Carvajal-Hausdorf D, Pelekanou V, Rehman J, Velcheti V, Herbst R,
LoRusso P and Rimm DL: Quantitative assessment of the heterogeneity
of PD-L1 expression in non-small-cell lung cancer. JAMA Oncol.
2:46–54. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Rehman JA, Han G, Carvajal-Hausdorf DE,
Wasserman BE, Pelekanou V, Mani NL, McLaughlin J, Schalper KA and
Rimm DL: Quantitative and pathologist-read comparison of the
heterogeneity of programmed death-ligand 1 (PD-L1) expression in
non-small cell lung cancer. Modern Pathol. 30:340–349. 2017.
View Article : Google Scholar
|
